CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor

被引：0
|
作者：
Philippe P. Pagni
Anitra Wolf
Mauro Lo Conte
Ronald Yeh
Guangsen Fu
Fa Liu
Matthias von Herrath
Ken Coppieters
机构：
[1] Novo Nordisk Research Center,
[2] Novo Nordisk A/S Research Projects,undefined
来源：
Diabetologia | 2019年 / 62卷
关键词：
CD40; CD40L; Type 1 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1727 / 1729
页数：2
相关论文
共 50 条
  • [41] Overview of the burden of illness and the role of once-weekly glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes
    Hinnen, Deborah
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 : S4 - S11
  • [42] CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes
    Vaitaitis, Gisela M.
    Waid, Dan M.
    Yussman, Martin G.
    Wagner, David H., Jr.
    IMMUNOLOGY, 2017, 152 (02) : 243 - 254
  • [43] Reduced efficacy of Glucagon-Like Peptide-1 Receptor Agonists therapy in people with type 1 diabetes and genetic forms of obesity (Apr, 10.1177/19322968241245680, 2024)
    Klein, M. P.
    Akturk, H. K.
    Snell-Bergeon, J. K.
    Shah, V. N.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [44] The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study
    Gameil, Mohammed Ali
    Yousef, Elshahat Ali Ahmed Mohamed
    Marzouk, Rehab Elsayed
    Emara, Mohamed H.
    Abdelkader, Abeer H.
    Salama, Rasha Ibrahim
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [45] Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action
    MohseniZadeh, S
    Binoux, M
    ENDOCRINOLOGY, 1997, 138 (12) : 5645 - 5648
  • [46] HEALTH CARE COSTS AMONG TYPE 2 DIABETES MELLITUS PATIENTS INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) THERAPY
    Johnston, S. S.
    Nguyen, H.
    Felber, E.
    Cappell, K.
    Nelson, J.
    Chu, B. C.
    Kalsekar, I
    VALUE IN HEALTH, 2014, 17 (03) : A244 - A244
  • [47] What are the early metabolic effects of combining duodenal exclusion and glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy in patients with Type 2 diabetes?
    Sen Gupta, P.
    Amiel, S. A.
    McGowan, B. M.
    Drummond, R. S.
    Bajwa, R. S.
    Blann, A. D.
    Ryder, R. E. J.
    DIABETIC MEDICINE, 2015, 32 : 98 - 98
  • [48] Plasma concentrations of soluble IL-2 receptor α (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients
    Kate Downes
    M. Loredana Marcovecchio
    Pamela Clarke
    Jason D. Cooper
    Ricardo C. Ferreira
    Joanna M. M. Howson
    Jennifer Jolley
    Sarah Nutland
    Helen E. Stevens
    Neil M. Walker
    Chris Wallace
    David B. Dunger
    John A. Todd
    Diabetologia, 2014, 57 : 366 - 372
  • [49] Plasma concentrations of soluble IL-2 receptor α (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients
    Downes, Kate
    Marcovecchio, M. Loredana
    Clarke, Pamela
    Cooper, Jason D.
    Ferreira, Ricardo C.
    Howson, Joanna M. M.
    Jolley, Jennifer
    Nutland, Sarah
    Stevens, Helen E.
    Walker, Neil M.
    Wallace, Chris
    Dunger, David B.
    Todd, John A.
    DIABETOLOGIA, 2014, 57 (02) : 366 - 372
  • [50] Adherence to Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Patients with Type 2 Diabetes Mellitus (T2DM)
    Johnston, Stephen
    Nguyen, Hiep
    Felber, Eugene
    Cappell, Katherine
    Nelson, James K.
    Chu, Bong-Chul
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A604 - A604
12345